Phase 1 trial, being conducted in the US, Canada and Denmark, will assess the most favorable KPT-330 dose to treat advanced hematologic malignancies.
Karyopharm founder, chief scientific officer and research and development president Sharon Shacham said, "KPT-330 and related SINE compounds have shown promising preclinical activity in several AML models, and we are hopeful that these results translate into benefits for patients with this devastating leukemia."
The trial, which includes non-Hodgkin’s lymphoma, multiple myeloma, Waldenstrom’s macroglobulinemia, and chronic lymphocytic leukemia patients with relapsed disease after standard therapies, now adds AML patients with either relapsed/refractory disease or who cannot take standard chemotherapies.